Related references
Note: Only part of the references are listed.Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease
Deborah Assouan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
Juan-Carlos Hernandez-Boluda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Elsa Lestang et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
Kate J. Newberry et al.
BLOOD (2017)
The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation
Marie Robin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Mohamed Shanavas et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis
H. Alchalby et al.
BONE MARROW TRANSPLANTATION (2016)
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
C. N. Harrison et al.
LEUKEMIA (2016)
Myelofibrosis: to transplant or not to transplant?
Rebecca Devlin et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review
Nosha Farhadfar et al.
JOURNAL OF ONCOLOGY PRACTICE (2016)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan H. Jagasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?
R. Tamari et al.
BONE MARROW TRANSPLANTATION (2015)
Pathogenesis of myeloproliferative neoplasms
Radek C. Skoda et al.
EXPERIMENTAL HEMATOLOGY (2015)
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2015)
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
N. M. Kroeger et al.
LEUKEMIA (2015)
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R. Zeiser et al.
LEUKEMIA (2015)
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2015)
CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies
Evgeny Klyuchnikov et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
Vikas Gupta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
N. Jaekel et al.
BONE MARROW TRANSPLANTATION (2014)
Allogeneic Stem Cell Transplant vs. Janus Kinase Inhibition in the Treatment of Primary Myelofibrosis or Myelofibrosis After Essential Thrombocythemia or Polycythemia Vera
Haefaa Alchalby et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Federico Lussana et al.
HAEMATOLOGICA (2014)
JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
T. Stuebig et al.
LEUKEMIA (2014)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
Annkristin Heine et al.
BLOOD (2013)
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Annkristin Heine et al.
BLOOD (2013)
Effects of spleen status on early outcomes after hematopoietic cell transplantation
G. Akpek et al.
BONE MARROW TRANSPLANTATION (2013)
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
Vikas Gupta et al.
BLOOD (2012)
Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
Donal P. McLornan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Improving Survival Trends in Primary Myelofibrosis: An International Study
Francisco Cervantes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Outcome of Transplantation for Myelofibrosis
Karen K. Ballen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
Haefaa Alchalby et al.
BLOOD (2010)
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
A. Bacigalupo et al.
BONE MARROW TRANSPLANTATION (2010)
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Nicolaus Kroeger et al.
BLOOD (2009)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis
N Kröger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Medical progress: Myelofibrosis with myeloid metaplasia.
A Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
